RIO DE JANEIRO - Johnson & Johnson (NYSE:JNJ (NYSE:JNJ)) revealed findings from the Phase 3 CARTITUDE-4 study, indicating that CARVYKTI (ciltacabtagene autoleucel) significantly improves overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma. According to the study, a single infusion of CARVYKTI reduced the risk of death by 45 percent compared to standard therapies.
The study enrolled patients who had previously received at least one line of therapy, including a proteasome inhibitor and immunomodulatory agent, and were refractory to lenalidomide. The results, featured at the International Myeloma Society Annual Meeting, showed a median overall survival that was not reached after a nearly three-year follow-up, demonstrating a sustained and durable response.
CARVYKTI's efficacy was highlighted by a 77 percent complete response rate and an 85 percent overall response rate. The study also reported a significant reduction in minimal residual disease, a key indicator of the depth of response to treatment. Safety profiles were consistent with previous analyses, with grade 3/4 treatment-emergent adverse events being primarily cytopenias.
The U.S. FDA and European Commission have approved CARVYKTI for the treatment of adult patients with relapsed or refractory multiple myeloma after at least one prior therapy line. Jordan Schecter, M.D., Vice President at Johnson & Johnson, emphasized the company's commitment to innovative treatments and the intention to submit these results to health authorities worldwide.
Multiple myeloma, an incurable blood cancer affecting plasma cells, is the third most common blood cancer globally. CARVYKTI, a BCMA-directed genetically modified autologous T-cell immunotherapy, represents a potential new standard of care for patients with multiple myeloma.
This article is based on a press release statement and aims to provide an unbiased, factual report of the study's findings.
In other recent news, Johnson & Johnson announced significant advancements in multiple myeloma treatment. The company revealed that DARZALEX FASPRO®, when used in combination with other drugs, has shown to improve patient outcomes in recent Phase 3 studies. Notably, the AURIGA study demonstrated that the combination of DARZALEX FASPRO® and lenalidomide more than doubled minimal residual disease (MRD)-negativity rates at 12 months for patients with newly diagnosed multiple myeloma.
Furthermore, the Phase 3 CEPHEUS study showed that DARZALEX FASPRO®, combined with other drugs, achieved a 60.9 percent MRD-negativity rate, significantly reducing the risk of disease progression or death. Additionally, the Phase 1b RedirecTT-1 study revealed promising efficacy for a novel bispecific antibody combination therapy in treating relapsed or refractory multiple myeloma.
In legal developments, Johnson & Johnson's subsidiary, Red River Talc LLC, filed for a prepackaged Chapter 11 bankruptcy as part of an $8 billion settlement strategy to resolve ongoing ovarian cancer claims related to cosmetic talc litigation in the U.S. In financial analysis, Goldman Sachs (NYSE:GS) reiterated its Buy rating on shares of CG Oncology, following new data presented by Johnson & Johnson. Lastly, the company announced the retirement of Executive Vice President and Chief Human Resources Officer, Dr. Peter M. Fasolo, with Kristen Mulholland named as his successor. These are recent developments at Johnson & Johnson.
InvestingPro Insights
Johnson & Johnson's latest breakthrough in multiple myeloma treatment aligns with its strong position in the pharmaceutical industry. According to InvestingPro data, the company boasts a substantial market capitalization of $389.28 billion, underscoring its significant presence in the healthcare sector.
An InvestingPro Tip highlights that J&J is a prominent player in the pharmaceuticals industry, which is evident from its innovative treatments like CARVYKTI. This aligns with the company's robust financial performance, including a revenue of $86.58 billion over the last twelve months and a healthy gross profit margin of 69.43%.
Another InvestingPro Tip notes that J&J has maintained dividend payments for 54 consecutive years, reflecting its financial stability and commitment to shareholder returns. This is particularly relevant given the company's ongoing investment in groundbreaking therapies like CARVYKTI.
For investors interested in a deeper analysis, InvestingPro offers 11 additional tips for Johnson & Johnson, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.